2021-11-162021-11-162006Avcı, R. vd. (2006). ''Intravitreal triamcinolone injection for chronic diffuse diabetic macular oedema''. Clinical and Experimental Ophthalmology, 34(1), 27-32.1442-64041442-9071https://doi.org/10.1111/j.1442-9071.2006.01103.xhttps://onlinelibrary.wiley.com/doi/10.1111/j.1442-9071.2006.01103.xhttp://hdl.handle.net/11452/22658Purpose: To determine the efficacy and safety of intravitreal triamcinolone in chronic diffuse diabetic macular oedema. Methods: This prospective, interventional consecutive case series study consisted of 59 eyes (36 patients) with chronic diffuse diabetic macular oedema, which received an intravitreal injection of 4 mg triamcinolone acetonide. The results were evaluated by clinical examination and fluorescein angiography. Potential complications such as a rise in intraocular pressure, cataract progression and endophthalmitis were recorded. Results: All patients completed at least 6 months follow up. The mean visual acuity improved significantly from 0.17 +/- 3.4 to a maximum of 0.30 +/- 3.3 at the third postinjection month (P < 0.01). Mean improvements in visual acuity measured were 2.15 +/- 1.66, 2.42 +/- 2.66, 1.13 +/- 2.74, 0.96 +/- 2.01 and 0.08 +/- 2.34 lines at the 1, 3, 6, 9 and 12 months follow-up intervals, respectively. In all eyes in fluorescein angiography, macular oedema was resolved (63%) or decreased (37%) during the follow up. However, the macular oedema reached the pretreatment level in 29 (49%) of the eyes at 6 months and 15 of 21 eyes (71%) at 9 months after injection. Intraocular pressure exceeded 21 mmHg in 10 eyes, which were controlled by topical medication. Four eyes showed cataract progression. Endophthalmitis was not observed in any of the eyes. Conclusions: Intravitreal injection of 4 mg triamcinolone acetonide appears to be an effective and relatively safe therapeutic method for diffuse diabetic macular oedema. Further studies are warranted to assess the long-term efficacy, safety and the need for reinjection.eninfo:eu-repo/semantics/closedAccessOphthalmologyTreatmentIntravitreal triamcinolone injectionDiffuse diabetic macular oedemaSafetyRemovalMembraneVitrectomyAcetonideVitreous bodyVisual acuityTriamcinolone acetonideTreatment outcomeProspective studiesAdultMiddle agedMaleMacular edema, cystoidInjectionsHumansGlucocorticoidsFollow-up studiesFluorescein angiographyFemaleDiabetic retinopathyChronic diseaseAgedArticle0002346653000072-s2.0-33644919953273234116451255OphthalmologyAflibercept; Ranibizumab; Macular DegenerationTriamcinolone acetonideTriamcinoloneTopical agentVisual acuityAdultProspective studyMaleIntraocular hypertensionInjectionHumanFollow upFluorescence angiographyFemaleEndophthalmitisDrug safetyDrug efficacyDiabetic macular edemaClinical trialAgedArticleCataractChronic diseaseClinical articleClinical examination